NeoGenomics (NASDAQ:NEO) Given New $19.00 Price Target at Needham & Company LLC

NeoGenomics (NASDAQ:NEO – Get Free Report) had its target price decreased by equities research analysts at Needham & Company LLC from $24.00 to $19.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s price target indicates […]

Related Keywords

United Kingdom ,United States ,Aliciac Olivo ,William Blair ,Piper Sandler ,Needham Company ,Burkett Financial Services ,Quadrant Capital Group ,Clinical Services ,Neogenomics Inc ,Financial Services Group Inc ,Neogenomics Company Profile ,Goldman Sachs Group ,Bluepath Capital Management ,Get Free Report ,General Counsel Alicia ,Path Capital Management ,Financial Services ,Capital Group ,Services Group ,Advanced Diagnostics ,Neogenomics Daily ,Neogenomics ,Nasdaq Neo ,Neo ,Medical ,Lower Price Target ,Needham Company Llc ,